KORU Medical Names New CEO as Longtime Leader Retires
Event summary
- Linda Tharby, KORU Medical's CEO for five years, will retire on June 30, 2026.
- Adam Kalbermatten, current Chief Commercial Officer, will take over as CEO on July 1, 2026.
- Tharby doubled the company's recurring patient base to 55,000 during her tenure.
- Kalbermatten brings 20 years of experience in medical devices and pharmaceuticals.
The big picture
KORU Medical's CEO transition reflects a strategic shift towards accelerating growth in the subcutaneous drug delivery market. The move comes as the company seeks to expand its Freedom infusion platform beyond immunoglobulin, leveraging Kalbermatten's extensive experience in commercializing medical technologies. The transition underscores the importance of operational discipline and strategic vision in maintaining market leadership.
What we're watching
- Leadership Transition
- How Adam Kalbermatten's commercial background will shape KORU's growth strategy.
- Strategic Execution
- Whether KORU can sustain its momentum in expanding drug classes beyond immunoglobulin.
- Market Positioning
- The pace at which KORU can strengthen its leadership in subcutaneous drug delivery.
Related topics